Tropical Medicine and Hepatology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Department of Tropical Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
J Med Virol. 2021 May;93(5):3176-3183. doi: 10.1002/jmv.26880. Epub 2021 Mar 11.
This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non-randomized controlled trial included 62 patients on the triple combination treatment versus 51 age- and sex-matched patients on routine supportive treatment. all of them confirmed cases by positive reverse-transcription polymerase chain reaction of a nasopharyngeal swab. Trial results showed that the clearance rates were 0% and 58.1% on the 7th day and 13.7% and 73.1% on the 15th day in the supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates on the 15th day are 13.7% and 88.7% in the supportive treatment and combined antiviral groups, respectively. This trial concluded by stating that the combined use of nitazoxanide, ribavirin, and ivermectin plus zinc supplement effectively cleared the SARS-COV2 from the nasopharynx in a shorter time than symptomatic therapy.
本试验比较了接受硝唑尼特、利巴韦林和伊维菌素加锌联合治疗与接受支持性治疗的患者的病毒清除率和时间。这项非随机对照试验纳入了 62 例三联治疗患者和 51 例年龄和性别匹配的接受常规支持性治疗的患者。所有患者均通过鼻咽拭子的逆转录聚合酶链反应阳性确诊。试验结果显示，在支持性治疗组和联合抗病毒组中，第 7 天的清除率分别为 0%和 58.1%，第 15 天的清除率分别为 13.7%和 73.1%。第 15 天的累积清除率分别为 13.7%和 88.7%。该试验得出结论，硝唑尼特、利巴韦林和伊维菌素加锌补充剂的联合使用比对症治疗更有效地在更短的时间内从鼻咽部清除 SARS-COV2。
